Shionogi & Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Shionogi & Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Shionogi & Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Shionogi & Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan, North America, and Europe. Shionogi is headquartered in Osaka, Japan.
Headquarters
Japan
Address
3-1-8, Dosho-Machi, Chuo-Ku, Osaka, 541-0045
Website
www.shionogi.com/jp
Telephone
81 6 62022161
No of Employees
4,955
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4507 (TYO)
Revenue (2025)
$3.2B
14%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
20.4%
(2025 vs 2024)
Market Cap*
$16.8B
Net Profit Margin (2025)
XYZ
5.6%
(2025 vs 2024)
* As of and is in US$
Shionogi & Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Prescription Drugs: | Contract Manufacturing Services | Rizmoic |
| Crestor | Symproic | |
| Cymbalta | Simploic | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In September, the company secured marketing authorization from the Therapeutic Goods Administration for cefiderocol, a siderophore cephalosporin to treat patients with carbapenem-resistant Gram-negative bacterial infections. |
| 2026 | Others | In August, the company agreed with SUSMED Co., Ltd. to terminate the commercialization agreement for a Digital Therapeutic Application for Insomnia. |
| 2026 | Others | In August, the company along with with FRONTEO and Nippon Life, deployed the AI-driven TalkLab KIBIT app. |
Competitor Comparison
| Key Parameters | Shionogi & Co Ltd | Takeda Pharmaceutical Co Ltd | Daiichi Sankyo Co Ltd | Otsuka Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka | Chuo-Ku | Chuo-Ku | Chiyoda-Ku | Chuo-Ku |
| State/Province | Osaka | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 4,955 | 47,029 | 20,171 | 6,070 | 7,872 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Isao Teshirogi, Ph.D. | Chairman; Chief Executive Officer; Director; President | Executive Board | 2022 | 67 |
| Keiichi Ando | Chairman | Executive Board | - | 75 |
| John Keller | Director; Senior Executive Officer; Senior Vice President - R&D Supervisory Unit | Executive Board | 2025 | 62 |
| Takeshi Shiota, Ph.D | Corporate Officer; Senior Vice President - Corporate Quality Assurance and Ethics & Compliance Management Division | Senior Management | - | - |
| Tatsumori Yoshida | Corporate Officer; Senior Vice President - Pharmaceutical Technology Research Division | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer